Soft Tissue Sarcoma Market Size is Expected to Increase With a CAGR of 6.47% During Study Period for 7MM as per DelveInsight's Analysis
- The increased market size is consequence of increasing incidence, expected launch of potential therapies, and precision medicine approach that will lead to more effective therapies
LAS VEGAS, Jan. 30, 2020 /PRNewswire/ -- DelveInsight added a new report titled "Soft Tissue Sarcoma Market Insight, Epidemiology and Market Forecast-2030" to its Market report portfolio. The report provides Soft Tissue Sarcoma (STS) Market Analysis, Market Size Forecast, detailed Epidemiology analysis and forecast, information related to Leading Companies along with the Competitive Analysis.
Some of the key highlights of the Soft Tissue Sarcoma market report are:-
- Soft Tissue Sarcoma total incident population in seven major markets was 40,155 in 2017.
- Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases.
- In the European countries, Germany had the highest Soft Tissue Sarcoma incident population with followed by Italy.
- The current Soft Tissue Sarcoma market size is mainly attributed by Votrient, Yondelis, Halaven and various Anthracycline and non-Anthracycline regimens.
- The Soft Tissue Sarcoma market size is increasing with a significant CAGR of 6.47% during the forecast period for 7MM
Get a sample report on Soft Tissue Sarcoma Market: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Soft-tissue sarcoma are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). Soft tissue sarcoma epidemiology is segmented by gender-specific incidence, type-specific incidence, age-specific, stage-specific, and extremities.
The different types of Soft Tissue Sarcoma that are included in the report are Leiomyosarcoma, followed by Fibroblastic sarcomas, and synovial sarcoma. The total Soft Tissue Sarcoma incidence cases in the United States were 2,961 cases of Leiomyosarcoma, followed by Fibroblastic sarcomas, and synovial sarcoma.
The age-specific incidence group include less than 20 years, 21–54 years, and 55 plus years. It is estimated that the most incident age-group for Soft Tissue Sarcoma in the US was 55+ years in 2017. The patients of age groups 21–54 years were observed to be the second-highest in 2017.
The stage-specific incidence in the US estimated the localized stage accounted to be 60% of overall Soft Tissue Sarcoma cases in 2017. There were 7,434 cases of localized type, 2,354 cases of regional type, 1,859 cases of distant type, and 743 cases of unknown type.
To know more about STS epidemiology click here to receive a sample report.
The current treatment landscape of STS is mainly dependent on targeted therapy, chemotherapy, anti-angiogenesis drugs, and radiation therapy. But the approved therapies are not up to the mark as they are associated with significant side effects as well as inefficacy.
Pharmaceutical companies, like Blueprint Medicines Corporation, Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical, Karyopharm Therapeutics, Deciphera Pharmaceuticals, Philogen, GlaxoSmithKline, Epizyme, Eli Lilly and Company, Pfizer, Aadi Bioscience, Sierra Oncology, Nanobiotix, Taiho Oncology, Arog Pharmaceuticals, and Merck Sharp & Dohme are developing products that have the potential to change the STS treatment landscape.
The launch of the emerging therapies is expected to significantly impact Soft Tissue Sarcoma treatment scenario in the upcoming years (2020–2030). Among the 7MM, US accounts for the largest market size of STS, in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan.
Reasons to buy Soft Tissue Sarcoma Report:
- The Soft Tissue Sarcoma market report proffer an overview of pathophysiology, treatment algorithm including detailed chapters for marketed products and emerging therapies.
- The report includes historical as well as forecasted epidemiology in seven major markets (7MM) covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
- The detailed historical and forecasted market covering the seven major markets from 2017 to 2030.
- The STS report also covers the Soft Tissue Sarcoma pipeline analysis across different stages of development, different emerging trends and comparative evaluation of pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.
- Market size by therapies covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030 are also mentioned.
- The report features attribute analysis, SWOT, reimbursement scenario and KOL views.
Click Here to Get a sample page: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Soft Tissue Sarcoma Drugs covered
- Avapritinib (BLU-285)
- Anlotinib (AL3818)
- Selinexor
- Aldoxorubicin (INNO-206)
- Ripretinib (DCC-2618)
- Fibromun (In combination with Doxorubicin)
- Hensify (NBTXR3)
- Crenolanib
- TAS-116
- GSK3377794
- ADP-A2M4
- Tazemetostat (EPZ-6438)
- AMG 337
- GB226/APL-501
- Camsirubicin
And many others
Schedule a free WebEx demo of the report: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
The key players in Soft Tissue Sarcoma market are:
- Blueprint Medicines Corporation
- Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
- Karyopharm Therapeutics
- Deciphera Pharmaceuticals
- Philogen
- GlaxoSmithKline
- Epizyme
- Eli Lilly and Company
- Pfizer
- Aadi Bioscience
- Sierra Oncology
- Nanobiotix
- Taiho Oncology
- Arog Pharmaceuticals
- Merck Sharp & Dohme
And many others
Table of contents
1. Key Insights
2. Executive Summary of Soft Tissue Sarcoma
3. Soft Tissue Sarcomas Market Overview at a Glance
4. Soft Tissue Sarcoma Disease Background and Overview
5. Soft Tissue Sarcoma Epidemiology and Patient Population
6. Case Reports
7. Country Wise Soft Tissue Sarcoma Epidemiology
7.1. United States Soft Tissue Sarcoma Epidemiology
7.2. EU5 Epidemiology
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan Epidemiology
8. Soft Tissue Sarcoma Treatment and Management
9. Unmet Needs in Soft Tissue Sarcoma
10. Soft Tissue Sarcoma Marketed Drugs
10.1. Halaven (Eribulin Mesylate): Eisai
10.2. Gleevec (Imatinib Mesylate): Novartis
10.3. Yondelis (Trabectedin): Pharma Mar
10.4. Lartruvo (Olaratumab): Eli Lilly
10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
10.6. Stivarga (Regorafenib): Bayer
10.7. Sutent (Sunitinib malate): Pfizer
10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis
10.9. Vincristine Sulfate: Hospira
10.10. Rozlytrek (Entrectinib): Roche (Genentech)
11. Soft Tissue Sarcoma Emerging Drugs
11.1. Key Cross Competition- Phase III Emerging Molecules
11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation
11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis
11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
11.5. Selinexor: Karyopharm Therapeutics
11.6. Aldoxorubicin (INNO-206): CytRx
11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals
11.8. Fibromun (In combination with Doxorubicin): Philogen
11.9. Hensify (NBTXR3): Nanobiotix
11.10. Crenolanib: Arog Pharmaceuticals
11.11. TAS-116: Taiho Pharmaceutical
11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune
11.13. ADP-A2M4: Adaptimmune
12. Soft Tissue Sarcoma 7 Major Market Analysis
13. Soft Tissue Sarcoma Market Outlook: The United States
13.1. United States Market Size
14. Soft Tissue Sarcoma Market Outlook: Europe
14.1. Germany
14.2. France
14.3. Italy
14.4. Spain
14.5. United Kingdom
15. Soft-Tissue Sarcoma Market Outlook: Japan
16. Access and Reimbursement Overview of Soft Tissue Sarcoma
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsightAbout DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Related reports
The Soft Tissue Sarcoma epidemiology covered in the report provides historical as well as forecasted Soft Tissue Sarcoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The Soft Tissue Sarcoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Soft Tissue Sarcoma across the complete product development cycle, including all clinical and nonclinical stages.
Contact us:
Shruti Thakur
[email protected]
+919650213330
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN05362&Transmission_Id=202001300918PR_NEWS_EURO_ND__EN05362&DateId=20200130)
Share this article